Saturday, October 3, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· January 8, 2026

Croissance organique de +6,0 % au premier trimestre 2026 - Confirmation des objectifs annuels

View original at globenewswire.com
Croissance organique de +6,0 % au premier trimestre 2026 - Confirmation des objectifs annuels Communiqué de presse Roubaix, 8 janvier 2026 Croissance organique de +6,0 % au premier trimestre 2026 Confirmation des objectifs annuels Chiffre d’affaires par segment de produits (en millions d'euros)2025 1er trimestre2026 1e…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Company is structured toward new target of €2 billion revenue

    80% confidence

  • Net revenue retention rate reached 105% on a comparable basis

    80% confidence

  • Q1 revenue exceeded €275 million with 6.0% organic growth

    80% confidence

  • OVHcloud confirms all FY2026 objectives including positive Free Cash-Flow generation

    80% confidence

  • Supply chain optimization initiated in 2025 allows continued service delivery while respecting investment envelope

    80% confidence

  • Group maintained operational and financial discipline, particularly on general and administrative expense control

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com